When using immunosuppressant drugs as an organ transplant recipient, it is crucial to effectively and consistently monitor drug levels. This requires therapeutic drug monitoring and an understanding of requirements and best practices for therapeutic drug monitoring in the laboratory.
Therapeutic drug monitoring (TDM) for immunosuppressive drugs (ISPs) is a critical component of post-tissue and organ transplantation therapy. This is because ISP drugs have high intra- and inter-subject variability and a narrow therapeutic window. Initially, quantitative analyses of ISPs such as sirolimus, cyclosporine A, tacrolimus, and everolimus used whole blood specimens.
When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy. The goal is to attain an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present varying pharmacodynamics and pharmacokinetics, so achieving this goal can be challenging.
For many organ transplant patients, immunosuppressant monitoring is a fact of life. But that does not mean that it cannot be significantly improved. For proof, look no further than the remote blood sampling capabilities provided by Mitra® microsampling devices, driven by Volumetric Absorptive Microsampling (VAMS®) technology.
Capillary Blood Microsampling in Anti-doping Research
In the arena of athletic competition, curtailing the use of anabolic steroids is one of the most significant challenges. This category includes the performance-enhancing substances that athletes most commonly abuse in the interest of gaining an unfair advantage.
Topics: Remote Patient Monitoring
Patient-centric healthcare has taken center-stage. With the increasing access to information, patients want to play a role in treatment methods and applications. Patient-centric sampling has an important part to play.